 Taysha Gene Therapies Inc NASDAQ: TSHA has unveiled a deal for global rights to the AAV9 gene therapy program, now known as TSHA-120, to treat giant axonal neuropathy GAN Under the terms of the agreement, the GAN patient advocacy group will receive an upfront payment of 5.5 million. It will be eligible to receive up to 19.3 million in milestone payments, as well as sales-based royalty. 